KALV Share Price Performance
US$14.91
5.13 (52.45%)
51.9% undervalued intrinsic discount
US$31.00
Fair Value
Price US$14.91
AnalystConsensusTarget US$31.00
AnalystLowTarget US$22.82
AnalystHighTarget US$39.00
Fair ValueUS$31.00
Share Pricen/a
KalVista Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
KALV Community Narratives
AN
Fair Value US$31 51.9% undervalued intrinsic discount
Oral Hereditary Angioedema Shift And Global Expansion Will Reshape This Undervalued Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$22.82 34.7% undervalued intrinsic discount
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$39 61.8% undervalued intrinsic discount
Oral HAE Therapies Will Transform Global Treatment And Drive Long-Term Market Leadership
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals develops oral therapies for hereditary angioedema, including EKTERLY for on demand treatment of HAE attacks. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$22.82
34.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
522.23% p.a.
Profit Margin
17.03%
Future PE
25.6x
Price in 2029
US$28.24
Oral Hereditary Angioedema Shift And Global Expansion Will Reshape This Undervalued Opportunity
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals is a biopharmaceutical company focused on oral therapies for hereditary angioedema, including its on demand treatment EKTERLY. What are the underlying business or industry changes driving this perspective?Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$31
51.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
492.89% p.a.
Profit Margin
3.6%
Future PE
190.03x
Price in 2029
US$38.35
Oral HAE Therapies Will Transform Global Treatment And Drive Long-Term Market Leadership
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals develops and commercializes oral therapies for hereditary angioedema to replace burdensome injectable treatments worldwide. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$39
61.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
707.13% p.a.
Profit Margin
0.99%
Future PE
349.35x
Price in 2028
US$48.21
Trending Discussion
Recently Updated Narratives
AN
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
Fair Value: US$22.82 34.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Oral Hereditary Angioedema Shift And Global Expansion Will Reshape This Undervalued Opportunity
Fair Value: US$31 51.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Oral HAE Therapies Will Transform Global Treatment And Drive Long-Term Market Leadership
Fair Value: US$39 61.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
KalVista Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jul 31, 2025
Next Reporting Earnings
n/a
- -4.02
- -4,166.97%
- -14,242.43%
- 324.4%
About KALV
- Founded
- n/a
- Employees
- 270
- CEO
- WebsiteView website
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
